CPP 115

Drug Profile

CPP 115

Alternative Names: CPP-115

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwestern University
  • Developer Catalyst Pharmaceutical
  • Class Aminobutyric acids; Antiepileptic drugs; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gilles de la Tourette's syndrome
  • Phase I Infantile spasms; Partial epilepsies
  • Preclinical Drug abuse

Most Recent Events

  • 16 Mar 2017 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (PO) (Catalyst Pharma pipeline, March 2017)
  • 19 Sep 2016 Efficacy data from a phase I trial in Infantile spasms released by Catalyst Pharmaceuticals
  • 16 Dec 2015 Top-line adverse events and pharmacodynamics data from a phase Ib trial in Healthy volunteers released by Catalyst Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top